CNS vs VTGN: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CNS and VTGN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CNS and VTGN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Cohen & Steers is a global investment manager founded in 1986 that specializes in real assets and alternative income, including listed real estate (REITs), infrastructure, preferred securities, and multi-strategy real assets. It organized the first US real estate securities mutual fund and remains one of the largest managers of REIT securities in the world, with roughly two-thirds of assets in listed real estate. The firm earns management fees on the assets it runs across open-end funds, closed-end funds, institutional accounts, and newer vehicles like its non-traded REIT (CNSREIT).

Full CNS guide

VistaGen Therapeutics is a clinical-stage biopharmaceutical company working on treatments for anxiety, depression, and other central nervous system conditions. Its platform is built around intranasal compounds it calls pherines, which are designed to act rapidly through nerve receptors in the nose without needing to be absorbed systemically into the bloodstream. Because it is pre-revenue, VistaGen has no product sales to speak of, and its results are dominated by research and development spending and net losses rather than profit.

Full VTGN guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• CNS drivers: Rate-cut tailwind for real assets; Return to organic growth.
• VTGN drivers: Fasedienol Phase 3 outcomes; Novel pherine mechanism.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: CNS revenue is almost entirely tied to AUM, so equity or bond market drawdowns directly cut fees and earnings. For VTGN, the overriding risk is clinical and binary: VistaGen has no approved products, and multiple Phase 3 fasedienol trials have missed their primary endpoints, so the entire thesis could collapse on a single disappointing readout or a negative regulatory response.

Pick CNS if you believe its drivers more; VTGN if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CNS and VTGN guides.

CNS. As of April 2026, CNS traded around a mid-20s price-to-earnings multiple with a dividend yield near 3.7%, reflecting its status as a profitable, dividend-paying specialty manager. Q1 2026 revenue of about $145.6 million grew roughly 8% year over year, and operating margin improved to about 34%. Because fees scale with AUM, valuation and earnings hinge on the direction of markets and flows into real-asset strategies.

VTGN. Figures are approximate and tied to the asOf date; verify live numbers before acting. Traditional valuation ratios like P/E do not apply to a pre-revenue, loss-making biotech. What matters is the probability-weighted value of the pipeline, the odds and timing of upcoming trial readouts, and whether cash lasts until those catalysts. A very low share price and small market cap also raise the practical risk of a reverse split or delisting, which are separate from the science.

Headline figures (approximate, APRIL 2026): CNS shows assets under management ~$93.1B, revenue (q1 2026) ~$145.6M, q1 2026 net inflows ~$497M, diluted eps (q1 2026) ~$0.82; VTGN shows revenue Effectively none; VistaGen is pre-revenue with no marketed products, so it reports operating losses driven by R&D spending, profitability Consistently unprofitable, as expected for a clinical-stage biotech; net losses fund ongoing trials, cash position Roughly $45 million in cash and equivalents reported at March 31, 2026, said to fund operations into 2027, market cap Micro-cap; the stock traded well under $1 in mid-2026, implying a very small market value and heightened listing-standard risk.

CNS and VTGN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CNS and VTGN exposure against your real portfolio. It is not an investment adviser.